PT Bio Farma
- Country
- 🇮🇩Indonesia
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.biofarma.co.id
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 188
- Registration Number
- NCT04741828
- Locations
- 🇮🇩
Puskesmas Jatinegara, Jakarta, Indonesia
🇮🇩Puskesmas Senen, Jakarta, Indonesia
Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine
- Conditions
- SARS-CoV2 Infection
- Interventions
- Biological: PlaceboBiological: SARS-CoV-2 vaccine (inactivated)
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 1620
- Registration Number
- NCT04508075
- Locations
- 🇮🇩
Hasan Sadikin Hospital/School of Medicine, Padjadjaran University, Bandung, West Java, Indonesia
Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children
- Conditions
- Hepatitis B
- Interventions
- Biological: Recombinant Hepatitis B (Bio Farma) VaccineBiological: Recombinant Hepatitis B (Bio Farma) Vaccine®
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 100
- Registration Number
- NCT04188223
- Locations
- 🇮🇩
Hasan Sadikin Hospital, Bandung, West Java, Indonesia
Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates
- Conditions
- Rotavirus Gastroenteritis
- Interventions
- Other: PlaceboBiological: Rotavirus RV3 Vaccine (Bio Farma)
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 1400
- Registration Number
- NCT04185545
- Locations
- 🇮🇩
Gantiwarno Primary Health Center, Yogyakarta, Indonesia
🇮🇩Gajahan Primary Health Center, Surakarta, Indonesia
🇮🇩Gambirsari Primary Health Center, Surakarta, Indonesia
Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
- Conditions
- MeaslesCongenital Rubella Infection
- Interventions
- Biological: Measles-Rubella vaccine Bio FarmaBiological: MR Vaccine SII
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 540
- Registration Number
- NCT04183114
- Locations
- 🇮🇩
Child Health Dept. Dr. Soetomo Hospital, School of Medicine Airlangga Univ., Surabaya, East Java, Indonesia
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B
- Conditions
- SafetyImmunogenicity
- Interventions
- Biological: Recombinant Hepatitis B + DTP-HB-HibBiological: Hep B + Pentabio (registered)
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 220
- Registration Number
- NCT04071379
- Locations
- 🇮🇩
Ibrahim Adjie Primary Health Centre, Bandung, West Java, Indonesia
🇮🇩Garuda Primary Health Centre, Bandung, West Java, Indonesia
🇮🇩Puter Primary Health Care, Bandung, West Java, Indonesia
Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)
- Conditions
- Safety IssuesImmunogenicity
- Interventions
- Biological: Vi-DT Typhoid Conjugate VaccineBiological: PQed Typhoid Conjugate VaccineBiological: Vi Polysaccharide Vaccine
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 3071
- Registration Number
- NCT04051268
- Locations
- 🇮🇩
Jatinegara Primary Health Care, Jakarta, Jakart, Indonesia
Protectivity and Safety Following Recombinant Hepatitis B Vaccine
- Conditions
- Immunogenicity
- Interventions
- Biological: Recombinant Hepatitis B vaccineBiological: Recombinant Hepatitis B (Bio Farma)
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 536
- Registration Number
- NCT03919578
- Locations
- 🇮🇩
RSND, Semarang, Central Java, Indonesia
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
- Conditions
- Safety IssuesImmunogenicity
- Interventions
- Biological: Measles-Rubella (MR) Vaccine
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 590
- Registration Number
- NCT03680417
- Locations
- 🇮🇩
Child Health Dept. Dr. Soetomo Hospital, School of Medicine Airlangga Univ., Surabaya, East Java, Indonesia
Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates
- Conditions
- Safety Issues
- Interventions
- Biological: Rotavirus (Bio Farma) VaccineOther: Placebo
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- PT Bio Farma
- Target Recruit Count
- 100
- Registration Number
- NCT03462108
- Locations
- 🇮🇩
Gantiwarno Primary Health Center, Klaten, Central Java, Indonesia
🇮🇩Klaten Selatan Primary Health Center, Klaten, Central Java, Indonesia
🇮🇩Ngawen Primary Health Center, Klaten, Central Java, Indonesia